Hiesse C, Rieu P, Neyrat N, Charpentier B, Benoit G, Bellamy J, Fries D
Service de Néphrologie, Hôpital Paul Brousse, Villejuif.
Nephrologie. 1987;8(3):127-9.
A prospective study was conducted on 57 high-risk patients having received cadaver renal transplants between January 1983 and May 1984, and submitted to the triple combination: cyclosporine, azathioprine, and steroids. 23 patients of Group I including 12 pre-sensitized and poorly matched recipients were treated from the Day 1 post-transplant. 34 patients of Group II received the triple combination following a steroid-ALG resistant rejection. Actuarial graft survival in the whole group was 74%, 64%, and 64% at 1, 2, and 3 years respectively. Patient survival was 100% in the Group I, vs 85% at 1 year, and 82% at 2 years in the group II (p less than 0.02). The incidence of infectious complications and infectious deaths was significantly higher in patients of Group II. Our results suggest the effectiveness of a triple low-doses combination in high-risk renal transplantation, but the delayed use of this combination following a treatment with high-doses of steroids and ALG fails to reverse the rejection, with an obvious overimmunosuppression risk.
对1983年1月至1984年5月间接受尸体肾移植的57例高危患者进行了一项前瞻性研究,这些患者接受了环孢素、硫唑嘌呤和类固醇的三联组合治疗。第一组23例患者,包括12例预先致敏且配型不佳的受者,从移植后第1天开始治疗。第二组34例患者在发生对类固醇-抗淋巴细胞球蛋白耐药的排斥反应后接受三联组合治疗。全组移植肾的精算生存率在1年、2年和3年时分别为74%、64%和64%。第一组患者的生存率为100%,而第二组在1年时为85%,2年时为82%(p<0.02)。第二组患者感染并发症和感染性死亡的发生率明显更高。我们的结果表明三联低剂量组合在高危肾移植中有效,但在大剂量类固醇和抗淋巴细胞球蛋白治疗后延迟使用该组合未能逆转排斥反应,且存在明显的过度免疫抑制风险。